For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Require Pharma to Disclose More Categories of Physician Payments under Clinical Trials Act
January 30, 2024
-
REGULATORY Chuikyo to Discuss Exclusion of Long-Listed Biologics from New Coverage Scheme
January 29, 2024
-
REGULATORY Break-Up of LDP Factions Won’t Have Major Impact on Pharma Policy, but Could Make Lobbying Tougher
January 26, 2024
-
BUSINESS Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area
January 26, 2024
-
ORGANIZATION JGA Chief Wary of “Full” Off-Year Revision in 2025, Urges Broader Exemptions If Plan Goes Forward
January 25, 2024
-
BUSINESS Ono Revs Up to Boost Global Presence, Launches New HR Scheme
January 24, 2024
-
COMMENTARY Goals of the “Innovation Box” Tax Break in FY2024 Reform
January 23, 2024
-
ACADEMIA Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
-
BUSINESS LEO Pharma Poised to Build Presence in Japan as Dermatology Leader: CEO
January 19, 2024
-
REGULATORY Market Expansion Re-Pricing to Hit 23 Meds in April, Opdivo Faces Yet Another Cut in Spillover
January 18, 2024
-
BUSINESS Sawai Exits US Biz to Cope with GMP and Supply Issues in Japan
January 18, 2024
-
BUSINESS Ono Deplores Regulator’s Decision on Opdivo Spillover Re-Pricing
January 18, 2024
-
BUSINESS Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
-
REGULATORY MHLW Issues Notification to Clarify Orphan Designation Criteria
January 17, 2024
-
COMMENTARY Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
REGULATORY FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig
January 16, 2024
-
REGULATORY New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief
January 15, 2024
-
BUSINESS GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
-
BUSINESS Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
-
REGULATORY MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources
January 11, 2024
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…